Remedium Bio

Executive Summary

Remedium Bio is a privately held biotechnology company based in Cambridge, MA, founded in 2020. The company is pioneering adjustable gene therapies through its proprietary Prometheus™ platform, which allows for post-treatment dose adjustment to enhance safety and durability. Remedium Bio's pipeline targets large unmet medical needs across endocrinology, neurology, rheumatology, and immunology. As an early-stage company with no disclosed funding or clinical-stage assets, Remedium Bio represents a preclinical or discovery-phase opportunity in the gene therapy space. The adjustable nature of its platform could differentiate it from conventional gene therapies, but the lack of publicly available data on specific programs or funding history introduces significant uncertainty.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Announcement60% success
• 2027First Investigational New Drug (IND) Filing30% success
• Q3 2026Publication of Preclinical Proof-of-Concept Data50% success